Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Pharma
Dupixent COPD delay possible, Eylea down 2%, Regeneron says
The FDA has requested more efficacy data for Sanofi and Regeneron's Dupixent in COPD. Additionally, Eylea sales fell by 2% in the first quarter.
Kevin Dunleavy
May 2, 2024 12:00pm
Regeneron, Sanofi tweak Dupixent message for latest asthma ads
Apr 29, 2024 7:00am
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent
Apr 26, 2024 7:39am
Sanofi is going all in on Dupixent's next potential nod in COPD
Apr 25, 2024 12:37pm
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
DOJ sues Regeneron for under-reporting Eylea price to Medicare
Apr 11, 2024 11:12am